PIONEER-AF-PCI Bleeding Algorithm Calculator

Clinical calculation support · Verify results before clinical use

Trial strategy explorer

Enter renal function and select the trial arm to review its regimen and published bleeding result.

TRIAL SUMMARY
Use estimated CrCl in mL/min (for example, Cockcroft–Gault). Patients with CrCl below 30 mL/min were excluded from PIONEER AF-PCI.
Clinical setting
Clinical setting is recorded for context; it does not alter the trial-level bleeding percentages displayed.
The intended DAPT duration was selected before randomization. Group 1 used a P2Y12 inhibitor without aspirin for 12 months.
PIONEER AF-PCI treatment group

How to interpret the trial results

PIONEER AF-PCI enrolled patients with nonvalvular atrial fibrillation who underwent PCI with stent placement. The primary safety endpoint was clinically significant bleeding during 12 months of follow-up.

Trial groupBleedingHazard ratio vs Group 3
Group 1: rivaroxaban + P2Y12 inhibitor16.8%0.59 (95% CI 0.47–0.76)
Group 2: rivaroxaban + DAPT strategy18.0%0.63 (95% CI 0.50–0.80)
Group 3: VKA + DAPT strategy26.7%Reference

Important limitations

  • These percentages describe trial groups; this calculator does not estimate an individual's bleeding probability.
  • The trial was not designed to establish definitive differences in ischemic efficacy between strategies; efficacy estimates had limited precision.
  • Patients with CrCl below 30 mL/min were excluded, limiting applicability to severe renal impairment.
  • Trial regimens should not be assumed to match currently approved doses for every indication or patient.

References

Gibson CM, Mehran R, Bode C, et al.Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. N Engl J Med. 2016;375:2423–2434. DOI: 10.1056/NEJMoa1611594. PMID: 27959713.
American College of Cardiology.PIONEER AF-PCI trial summary, including treatment arms, renal exclusion criterion, and bleeding outcomes. Read trial summary.
Clinical disclaimer: Educational and reference use only. This tool summarizes trial arms and published group-level bleeding outcomes; it does not recommend a regimen for an individual patient. Treatment after PCI in atrial fibrillation requires assessment of thromboembolic and ischemic risk, bleeding risk, renal function, drug interactions, contraindications, and current guideline and regulatory recommendations. Do not use the very-low-dose rivaroxaban trial regimen as a substitute for appropriate anticoagulation for AF stroke prevention without specialist review.